MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I



Status:Completed
Conditions:Breast Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:6/30/2018
Start Date:October 2011
End Date:June 2017

Use our guide to learn which trials are right for you!

Genomics assays that measure specific gene expression patterns in a patient's primary tumor
have become important prognostic tools for breast cancer patients. This study is designed to
test the ability of MammaPrint® in combination with TargetPrint®, BluePrint®, and
TheraPrint®, as well as traditional pathologic and clinical prognostic factors, to predict
responsiveness to neo-adjuvant chemotherapy in patients with locally advanced breast cancer
(LABC).

Patients with suspected primary breast cancer on mammography and clinical examination will be
assessed for eligibility by having a needle core biopsy to confirm invasive carcinoma.

A fresh unfixed tumor specimen, incisional or core biopsy will be sent to Agendia to
determine the MammaPrint risk profile, the BluePrint molecular subtyping profile, the
TargetPrint ER, PR and HER2 single gene readout, the 56-geneTheraPrint Research Gene Panel
and the additional genes as measured on the whole genome (44k) array.

Surgical Protocol:

1. Determination of nodal status:

- For clinically node-negative patients: Axillary ultra sound, followed by Sentinel
Lymph Node (SLN) biopsy

- For clinically node-positive patients: ultra sound-guided Fine Needle Aspirate
(FNA), followed by core biopsy

2. Neo-adjuvant chemotherapy

3. Definitive surgery:

- For node-positive patients: lumpectomy, repeat SLN biopsy, Axillary Lymph Node
Dissection (ALND)

- For node-negative patients: lumpectomy, repeat SLN biopsy (optional), no ALND

Response will be measured by pathological Complete Response (pCR) and by centrally assessed
Residual Cancer Burden (RCB).

Inclusion Criteria:

- Women with histologically proven invasive breast cancer and no distant metastases and;

- Lymphnode negative and a clinical tumor classification of T2 (≥3.5cm)-T4 or with 1-3
positive lymph nodes and a clinical tumor classification of T2-T4 DCIS or LCIS are
allowed in addition to invasive cancer at T2 or T3 level.

- Age ≥ 18 years.

- At least one lesion that can be accurately measured in two dimensions utilizing
mammogram, ultrasound, or MRI images to define specific size and validate complete
pathologic response.

- Adequate bone marrow reserves (neutrophil count >1.5 x109 /l and platelet count >100
x109/l), adequate renal function (serum creatinine ≤ 1.5 x upper limit of normal) and
hepatic function (ALAT, ASAT ≤ 2.5 x upper limit of normal, alkaline phosphatase ≤ 2.5
x upper limit of normal and total bilirubin ≤ 2.0 x upper limit of normal).

- Signed informed consent of the patient

Exclusion Criteria:

- Any patient with confirmed metastatic disease. Patients with inflammatory breast
cancer.

- Tumor sample shipped to Agendia with ≤ 30% tumor cells or that fails Quality Assurance
or Quality Control criteria.

- Patients who have had any prior chemotherapy, radiotherapy, or endocrine therapy for
the treatment of breast cancer.

- Any serious uncontrolled intercurrent infections, or other serious uncontrolled
concomitant disease.
We found this trial at
9
sites
?
mi
from
Plano, TX
Click here to add this to my saved trials
Miami, Florida 33124
(305) 284-2211
University of Miami A private research university with more than 15,000 students from around the...
?
mi
from
Miami, FL
Click here to add this to my saved trials
Bronx, New York 10469
?
mi
from
Bronx, NY
Click here to add this to my saved trials
Clearwater, Florida 33756
?
mi
from
Clearwater, FL
Click here to add this to my saved trials
?
mi
from
Columbus, OH
Click here to add this to my saved trials
1660 Springhill Avenue
Mobile, Alabama 36604
(251) 665-8000
University of South Alabama Mitchell Cancer Institute USA Mitchell Cancer Institute (MCI) is located in...
?
mi
from
Mobile, AL
Click here to add this to my saved trials
940 NE 13th St
Oklahoma City, Oklahoma 73190
(405) 271-6458
University of Oklahoma Health Sciences Center The OU Health Sciences Center is composed of seven...
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
?
mi
from
Tampa, FL
Click here to add this to my saved trials
1395 South Pinellas Avenue
Tarpon Springs, Florida 34689
?
mi
from
Tarpon Springs, FL
Click here to add this to my saved trials